T1	p 100 135	patients with early breast cancer :
T2	p 213 228	Group ( CECOG )
T3	p 323 347	with early breast cancer
T4	i 25 96	dose-dense FEC regimens with growth factor support for adjuvant therapy
T5	i 243 278	epirubicin to adjuvant chemotherapy
T6	i 474 514	fluorouracil/epirubicin/cyclophosphamide
T7	i 517 520	FEC
T8	i 551 554	FEC
T9	i 601 613	chemotherapy
T10	i 618 621	FEC
T11	i 696 732	intermediate dose-dense FEC regimens
T12	i 777 799	FEC ( 75 ) or FEC ( 90
T13	i 819 824	drugs
T14	i 886 904	pegfilgrastim 6 mg
T15	i 917 929	subcutaneous
T16	i 1124 1127	FEC
T17	i 1139 1142	FEC
T18	i 1179 1182	FEC
T19	i 1242 1245	FEC
T20	i 1413 1416	FEC
T21	i 1524 1527	FEC
T22	i 1759 1762	FEC
T23	i 1856 1872	dose-dense FEC (
T24	i 1882 1885	FEC
T25	o 646 654	toxicity
T26	o 977 985	efficacy
T27	o 1056 1074	dose intensity and
T28	o 1317 1365	adverse events and personal/logistical reasons .
T29	o 1370 1384	dose reduction
T30	o 1436 1486	to diarrhoea . Grade 3-4 haematological toxicities
T31	o 1555 1588	incidences of febrile neutropenia
T32	o 1624 1638	adverse events
T33	o 1654 1709	in liver enzymes and gastrointestinal events ; no event
T34	o 1749 1758	patient (
T35	o 1770 1839	) experienced serious adverse events ( vomiting and throat oedema ) .
T36	o 1989 2009	Grade 3-4 toxicity .